UNSPSC 51142413: Zolmitriptan

This classification denotes a serotonin agonist with the molecular formula C16H21N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2FS66TH3YW, chemically known as 2-oxazolidinone, 4-((3-(2-(dimethylamino)ethyl)-1h-indol-5-yl)methyl)-, (s)- but generally known as zolmitriptan, which bears US NIH Compound Identifier 60857. European Medicines Agency schedules Zolmitriptan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00181MIG.

UNSPSC 51142413 Zolmitriptan is a Commodity code tracking pharmaceutical products, but the recent state and local opportunities posted under this code do not reflect procurement of zolmitriptan specifically. Instead, the opportunities cover broader pharmaceutical procurement—naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing, and exploratory direct-to-manufacturer prescription programs. State and local issuing bodies soliciting under this code span county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving multiple states including Oregon). The work involves establishing supply contracts for pharmaceutical products through authorized wholesalers, with requirements for product compliance, pricing flexibility, cGMP and Drug Supply Chain Security Act certification, and specific insurance coverage thresholds.

Geographic activity centers on Florida, Texas, and Minnesota through the multistate cooperative vehicle. Representative recent opportunities include Seminole County's IFB60459723LAS (posted June 30, 2026, response due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding with quarterly deliveries; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) soliciting vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager arrangements; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026, response due March 26, 2026) establishing multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local facilities, with price competitiveness weighted at 75 percent of evaluation and awards effective July 1, 2026.